The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
The first TUB-040 data come just after Tubulis raised €308m.
Full data from Edge-Gastric are presented at ESMO.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
